iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. NUE
5. ONON
6. AAPL
7. TRMD
8. AZN
9. NVDA
10. USO

Go back to iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026
(NASDAQ: DTIL) Delayed: 6.63 -0.04 (0.6%)
Previous Close $6.67    52 Week High $ 
Open $6.65    52 Week Low $ 
Day High $6.87    P/E N/A 
Day Low $6.57    EPS $ 
Volume 64,333